Treatment of metastatic malignant melanoma with 24 hours continuous venous infusion of dacarbazine and cisplatin | Zendy

Icli Fikri | Zendy; Karaoguz Handan | Zendy; Dincol Dilek | Zendy; Gunel Nazan | Zendy; Demirkazik Ahmet | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Treatment of metastatic malignant melanoma with 24 hours continuous venous infusion of dacarbazine and cisplatin

Author(s) -

Icli Fikri,

Karaoguz Handan,

Dincol Dilek,

Gunel Nazan,

Demirkazik Ahmet

Publication year - 1991

Publication title -

journal of surgical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.201

H-Index - 111

eISSN - 1096-9098

pISSN - 0022-4790

DOI - 10.1002/jso.2930480312

Subject(s) - medicine , dacarbazine , melanoma , cisplatin , chemotherapy , oncology , metastatic melanoma , surgery , cancer research

Twenty consecutive patients with metastatic malignant melanoma were treated with a combination of 24 hours continuous infusion of dacarbazine (250 mg/m 2 ) and cisplatin (20 mg/m 2 ) for 5 days every 3 weeks. One patient (5%) achieved a complete response (CR) and 3 patients (15%) obtained a partial response (PR) with an overall response rate of 20%. Minimal response was observed in 5 other patients (25%). Complete response duration was 8 months. Median response duration of partial responders was 7 months. Median survival of all responders (CR+PR) was 8.5 months. Toxicity was mild to moderate.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research